Medical Treatment of Benign Prostatic Hyperplasia- BPH
α1-blockers
Will be offered to men to with moderate-to-severe lower urinary tract symptoms (LUTS).
Currently available medications are: tamsulosin, silodosin, terazosin, doxazosin, and alfuzosin.
5α-reductase inhibitors
Will be offered to men to with moderate-to-severe LUTS and a prostate volume > 40 mL.
Onset of action will be delayed for three to six months.
Currently available medications are: finasteride and dutasteride.
Muscarinic receptor antagonists
Will be offered to men with moderate-to-severe LUTS who mainly have bladder storage symptoms.
Will not be offered if post-void residual volume > 150 mL.
Currently available medications are:
oxybutynin, tolterodine, fesoterodine, solifenacin,
darifenacin, propiverine, and trospium.
Phosphodiesterase type 5 inhibitors
Will be offered to men with moderate-to-severe LUTS with or without erectile dysfunction.
Currently available medications for this purpose: tadalafil
Beta-3 agonists
Will be offered to men with moderate-to-severe LUTS who mainly have bladder storage symptoms.
Currently available medications: Mirabegron